Bank of America
CTXR icon

Bank of America’s Citius Pharmaceuticals CTXR Stock Holding History

Bank of America’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-307
Closed -$238 – 5988
2025
Q4 		$238 Sell
307
-115
-27% -$144 ﹤0.01% 6673
2025
Q3 		$523 Buy
422
+45
+12% +$63 ﹤0.01% 7581
2025
Q2 		$599 Buy
377
+309
+454% +$283 ﹤0.01% 7632
2025
Q1 		$101 Buy
68
+13
+24% +$31 ﹤0.01% 7828
2024
Q4 		$220 Sell
55
-1,102
-95% -$7.42K ﹤0.01% 7568
2024
Q3 		$14.5K Sell
1,157
-5,220
-82% -$87.8K ﹤0.01% 6813
2024
Q2 		$92.9K Buy
6,377
+4,289
+205% +$76.9K ﹤0.01% 6281
2024
Q1 		$46.8K Sell
2,088
-5,137
-71% -$93.8K ﹤0.01% 6539
2023
Q4 		$137K Buy
7,225
+3,082
+74% +$58.5K ﹤0.01% 6252
2023
Q3 		$70.8K Sell
4,143
-829
-17% -$19.7K ﹤0.01% 6383
2023
Q2 		$149K Buy
4,972
+4,971
+497,100% +$164K ﹤0.01% 6023
2023
Q1 		$23 Sell
1
-5
-83% -$144 ﹤0.01% 7561
2022
Q4 		$122 Buy
+6
New +$164 ﹤0.01% 7634
2022
Q3 		– Sell
-2
Closed -$55 – 7891
2022
Q2 		$0 Sell
2
-719
-100% -$19.7K ﹤0.01% 8071
2022
Q1 		$32K Sell
721
-3,504
-83% -$138K ﹤0.01% 7342
2021
Q4 		$162K Buy
4,225
+2,486
+143% +$113K ﹤0.01% 6612
2021
Q3 		$88K Buy
1,739
+276
+19% +$13.8K ﹤0.01% 6788
2021
Q2 		$127K Buy
+1,463
New +$87.9K ﹤0.01% 6379
2020
Q1 		– Sell
-65
Closed -$2K – 6905
2019
Q4 		$2K Sell
65
-158
-71% -$2.31K ﹤0.01% 6877
2019
Q3 		$5K Buy
223
+128
+135% +$3.37K ﹤0.01% 6845
2019
Q2 		$2K Buy
+95
New +$2.71K ﹤0.01% 6950
2019
Q1 		– Hold
0
– – – 7151
2018
Q4 		– Sell
-137
Closed -$4.69K – 7149
2018
Q3 		$6K Buy
+137
New +$6.54K ﹤0.01% 6779
2018
Q2 		– Hold
0
– – – 7110

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America's CTXR Position: Q1 2026 in Review

Bank of America sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 307 shares — an estimated $238 sold.

Bank of America first reported a position in CTXR in Q3 2018 and held it in 22 quarters. The position peaked at $162K in Q4 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Bank of America reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 307 Citius Pharmaceuticals shares in Q1 2026, an estimated $238.
  • Bank of America first reported a position in Citius Pharmaceuticals in Q3 2018 and held it in 22 quarters.
  • Bank of America's Citius Pharmaceuticals position peaked at $162K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.